Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
about
Molecular Targeted Therapies of Aggressive Thyroid CancerMedical management of metastatic medullary thyroid cancerLenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancerA phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylateSafety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.Multi-targeted approach in the treatment of thyroid cancer.Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.Is there something other than imatinib mesilate in therapeutic options for GIST?Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experienceCytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.Multikinase inhibitors use in differentiated thyroid carcinoma.The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer.A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.Antiangiogenic therapy for breast cancerImatinib therapy in chronic myelogenous leukemia and thyroid function tests.Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.Thyroid cancer: emerging role for targeted therapies.18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.Targeted treatment of differentiated and medullary thyroid cancer.New therapies for dedifferentiated papillary thyroid cancerAugmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanibAn open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancerA phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.Antiangiogenic therapies in early-stage breast cancer.Thyroid cancer: pathogenesis and targeted therapyAntitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft modelsThe VEGF pathway in cancer and disease: responses, resistance, and the path forward.Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.Emerging drugs for the treatment of metastatic renal cancer.Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone.RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
P2860
Q26774734-03FB082F-169D-4CE9-BB27-56A875DA632AQ27005897-0B57384A-8ED4-44D4-A445-4764422264D9Q28072655-C0F5329B-9985-4EE9-9819-3AE939655D9EQ30414010-ED71BA22-C2A8-4BC2-9D1D-0429F9747C88Q30557865-5F2D8579-F802-4409-84E1-B23F87764099Q30558610-76C07BED-EB8A-43E4-8C58-F467554E9198Q33666010-45BDF1EB-93F6-4150-B95B-EB506D1F9A1CQ33972047-B4AEDAD6-138A-4085-A813-DC1F0589A0D6Q33982413-47585413-F64A-481C-83B5-386BE5E0103EQ34031293-B9B1B3A1-45F5-4D90-88CE-142FB15E13D8Q34207379-4B042D31-D8E1-482F-A4CA-4EE0F9290A76Q34337865-3125A4EF-AC9A-4D41-A57D-7C3F38BB7593Q34340390-9889FFFA-C8F6-4B32-94F5-16AFB5E4BAE8Q34660901-95123044-499C-42DD-ADE0-43264FBF4002Q34725749-1A01439D-08FB-43E2-8F4F-C703F63014F9Q34923902-7C94FF4C-43F4-4141-AC7D-ED44C892D43BQ34956830-F5FE243B-F50B-4826-9205-4AADD6061DE1Q34989039-D0725536-2095-4DFB-9141-219406E94116Q35009270-2259432A-6EB2-4AA9-A021-30518DF733CCQ35069657-B70065C4-5659-4931-90F3-03B6DD921AFDQ35076227-1BF6A02A-AF0C-4F97-8289-9530D888E09AQ35094941-47C01F55-5508-4DF0-8791-B24B26D529B7Q35147151-7AE691B9-DAE0-410D-B508-D93FC6331A99Q35381593-263B04E5-CBA9-4171-A3DC-932C647B2F18Q35550182-141BC8BD-E1FB-4CCE-B4FF-2CC81039132CQ35584482-89C47EE5-4E25-4A40-8609-C1F38D923439Q35864072-E5978F8F-EDCD-4658-8D56-AEE04D792F07Q35883400-439C8150-E47C-4C41-8124-98F4BFD8F62FQ35996229-9A86C7CF-27F3-46E5-8E91-BE25C35E3F89Q36147155-723511C3-3CDA-4086-92B4-2613E6CEBC0AQ36275492-987F9A0C-0D9B-4734-A0E5-2B5D7839AE3EQ36318210-419520FE-7FBB-4F43-9594-4559A29FEAC7Q36328045-302C05AD-62CE-4DA8-81C3-B5244DCCA9AFQ36448279-8337C3A3-9179-4CD8-9F83-5B72B82E7656Q36526512-632EAED4-3B39-43B5-801A-67ECE40CF7C5Q36825455-1C449115-4296-4DBA-B291-1CADE42C20A2Q36965055-3506FCE3-B4CF-4288-840F-35F10B77390FQ36989925-36E2FE07-613F-4615-8EA1-C4626E01D39BQ36990587-3FA4ADC6-90B5-4E29-B87B-7461F98C6F0AQ37134454-71E3A1A7-A2A5-4492-8E0B-7662DE6D3A9A
P2860
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@ast
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@en
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@nl
type
label
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@ast
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@en
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@nl
prefLabel
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@ast
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@en
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@nl
P2093
P356
P1476
Safety, pharmacokinetics, and ...... ts with advanced solid tumors.
@en
P2093
Andy Van Vugt
Anthony Polverino
Antonis Koutsoukos
David D Chang
Jeffrey S Wiezorek
Jeffrey Silverman
Lee S Rosen
Marilyn Mulay
Michael B Bass
P304
P356
10.1200/JCO.2006.07.8170
P407
P577
2007-06-01T00:00:00Z